Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to $26.3 million.

  • Capricor Therapeutics' Operating Expenses rose 7211.15% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.8 million, marking a year-over-year increase of 2266.09%. This contributed to the annual value of $64.8 million for FY2024, which is 3162.95% up from last year.
  • Per Capricor Therapeutics' latest filing, its Operating Expenses stood at $26.3 million for Q3 2025, which was up 7211.15% from $27.7 million recorded in Q2 2025.
  • Over the past 5 years, Capricor Therapeutics' Operating Expenses peaked at $27.7 million during Q2 2025, and registered a low of $4.3 million during Q3 2021.
  • Moreover, its 5-year median value for Operating Expenses was $12.4 million (2023), whereas its average is $12.9 million.
  • Over the last 5 years, Capricor Therapeutics' Operating Expenses had its largest YoY gain of 12684.03% in 2021, and its largest YoY loss of 975.86% in 2021.
  • Capricor Therapeutics' Operating Expenses (Quarter) stood at $6.4 million in 2021, then skyrocketed by 41.49% to $9.0 million in 2022, then soared by 48.12% to $13.4 million in 2023, then surged by 40.83% to $18.8 million in 2024, then skyrocketed by 39.6% to $26.3 million in 2025.
  • Its Operating Expenses was $26.3 million in Q3 2025, compared to $27.7 million in Q2 2025 and $18.8 million in Q4 2024.